FDA approves Sagent's Granisetron

SCHAUMBURG, Ill. The Food and Drug Administration has approved a generic injectable drug made by Sagent Pharmaceuticals and used for sickness related to chemotherapy, Sagent announced Wednesday.

The FDA approved granisetron hydrochloride, for preventing nausea and vomiting caused by chemotherapy, in the 0.1 mg per milliliter, 1 mg per milliliter and 4 mg per milliliter strengths. The company plans to begin marketing the drug in third quarter 2010.

Granisetron had sales of $26 million in 2009, according to IMS Health, and is a generic version of Roche’s Kytril, which the FDA approved in 1993.